CD8A and neoplasm: As expected on the basis of correlations for individual regions (Data Supplement), applying this tumor average score to the combined stage II and III taxonomy cohort revealed that high levels of CD8+ lymphocytes identified CRIS-C patients with good prognosis (log-rank P = .0031; HR, 12.18 [Wald test P = .0191]; Fig 4A).